In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany Rows Back On Plans For Biosimilar Substitution

Executive Summary

Plans to allow German pharmacists to substitute biological drugs in the same way as they do small-molecule medicines have been watered down in the latest draft of healthcare reforms.

You may also be interested in...

Bio Substitution Plan Would Put Germany On ‘Wrong Track’

Plans for substituting biological drugs at pharmacy level that have been passed by Germany’s lower house of parliament threaten to undo the good work done to date in winning trust in biosimilars, local industry association Pro Biosimilars fears.

German draft offers firms pro and cons

Positive measures including a drive to increase uptake of biosimilars are offset by more negative aspects, such as promoting pharmacy substitution of biologics and exposing cytostatic cancer therapies to tender processes, under draft medicines legislation unveiled by Germany’s ministry of health.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts